Weekly roundup: Clinical breakthroughs, strategic appointments, and a dealmaker
Oncoinvent published Phase 1 study results for Radspherin® in ovarian cancer in Gynecologic Oncology
Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, announced the publication of 12-month data from its Phase 1 study of patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The results from the first patients have been published in the respected peer-reviewed journal Gynecologic Oncology.
Poolbeg Pharma plc – POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme
Poolbeg Pharma, a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announced that the POLB 001 TOPICAL trial is to feature in a groundbreaking University of Manchester and The Christie NHS Foundation Trust research programme into cancer immunotherapy-induced CRS alongside Johnson & Johnson and other partners.
Fibrocor Therapeutics appointed world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome
Fibrocor Therapeutics, a biotech company developing first-in-class therapies for kidney diseases, with a strong focus on Alport Syndrome, announced the appointment of four internationally recognised authorities on nephrology and genetics to its newly formed Clinical Advisory Board (CAB), underscoring the company’s accelerating momentum and scientific leadership.
📺Optimum TV
There was a double dose of Optimum TV this week, with episodes featuring Renée Aguiar-Lucander, CEO of Hansa Biopharma, and Otello Stampacchia, Founder and Managing Director of Omega Funds. Find out more about each episode below.
Some people who desperately need a kidney transplant have extreme difficulty being matched with a suitable donor organ, as they have very high levels of the antibody immunoglobulin (IgG), which often results in organ rejection. Hansa Biopharma is targeting this critical unmet medical need with its first-in-class candidate imlifidase. Watch below to learn more about Hansa’s approach including broader potential in gene therapy and rare autoimmune diseases.
Our ‘Dealmakers 2026’ series continued with Otello Stampacchia of Omega Funds, taking the temperature of the market ahead of the new year. Otello tells us he is “moderately” optimistic about 2026 as a whole, but adds that FOMO among pharma companies has driven a surge of M&A in late 2025 – which bodes well for the year ahead. Watch the full episode here.
🔥Hot topic
The obesity drugs Wegovy and Mounjaro have been the single biggest story in pharma over the last few years. But even these mega-blockbusters are imperfect from a patient’s point of view. A raft of new next generation treatments is now being developed – and the race to get them to market is heating up. Read more in this week’s Hot Topic. ⬇️
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
